NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00551928,Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients,https://clinicaltrials.gov/study/NCT00551928,MPRvsMEL200,COMPLETED,"To compare the efficacy of the combination of lenalidomide with low-dose melphalan versus high-dose melphalan in newly diagnosed, symptomatic MM patients.",NO,Multiple Myeloma|Newly Diagnosed Patients,DRUG: Melphalan|DRUG: Lenalidomide|DRUG: Prednisone|DRUG: Melphalan,"Progression free survival, 5 years","Over all survival, 5 years",,Fondazione EMN Italy Onlus,,ALL,"ADULT, OLDER_ADULT",PHASE3,402,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,RV-MM-PI-209,2007-06,2022-06,2024-07-01,2007-10-31,,2024-07-22,"Division of Hematology, AOU Citt√† della Salute e della Scienza di Torino, Torino, 10126, Italy",
